GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vistagen Therapeutics Inc (NAS:VTGN) » Definitions » E10

Vistagen Therapeutics (Vistagen Therapeutics) E10

: $-184.73 (As of Dec. 2023)
View and export this data going back to 2009. Start your Free Trial

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Vistagen Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.220. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-184.73 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 17.10% per year. During the past 5 years, the average E10 Growth Rate was 12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Vistagen Therapeutics was 17.10% per year. The lowest was 8.90% per year. And the median was 9.40% per year.

As of today (2024-04-23), Vistagen Therapeutics's current stock price is $4.78. Vistagen Therapeutics's E10 for the quarter that ended in Dec. 2023 was $-184.73. Vistagen Therapeutics's Shiller PE Ratio of today is .


Vistagen Therapeutics E10 Historical Data

The historical data trend for Vistagen Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vistagen Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
E10
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -367.98 -333.81 -309.37 -273.23 -190.15

Vistagen Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -199.05 -190.15 -190.74 -187.08 -184.73

Competitive Comparison

For the Biotechnology subindustry, Vistagen Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vistagen Therapeutics Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Vistagen Therapeutics's Shiller PE Ratio falls into.



Vistagen Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vistagen Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.22/129.4194*129.4194
=-0.220

Current CPI (Dec. 2023) = 129.4194.

Vistagen Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 -49.200 99.695 -63.869
201406 -111.000 100.560 -142.856
201409 -57.000 100.428 -73.455
201412 -32.400 99.070 -42.326
201503 -135.000 99.621 -175.381
201506 -576.900 100.684 -741.549
201509 -157.800 100.392 -203.427
201512 -58.500 99.792 -75.868
201603 -108.900 100.470 -140.278
201606 -15.300 101.688 -19.472
201609 -12.600 101.861 -16.009
201612 -10.200 101.863 -12.959
201703 -9.300 102.862 -11.701
201706 -8.400 103.349 -10.519
201709 -15.900 104.136 -19.760
201712 -7.500 104.011 -9.332
201803 -5.681 105.290 -6.983
201806 -6.000 106.317 -7.304
201809 -9.000 106.507 -10.936
201812 -7.200 105.998 -8.791
201903 -4.500 107.251 -5.430
201906 -4.500 108.070 -5.389
201909 -3.900 108.329 -4.659
201912 -4.500 108.420 -5.372
202003 -2.100 108.902 -2.496
202006 -2.100 108.767 -2.499
202009 -1.500 109.815 -1.768
202012 -2.100 109.897 -2.473
202103 -4.910 111.754 -5.686
202106 -1.200 114.631 -1.355
202109 -2.100 115.734 -2.348
202112 -1.500 117.630 -1.650
202203 -2.579 121.301 -2.752
202206 -2.870 125.017 -2.971
202209 -2.540 125.227 -2.625
202212 -1.420 125.222 -1.468
202303 -1.689 127.348 -1.716
202306 -0.940 128.729 -0.945
202309 -0.660 129.860 -0.658
202312 -0.220 129.419 -0.220

Add all the adjusted EPS together and divide 10 will get our e10.


Vistagen Therapeutics  (NAS:VTGN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Vistagen Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Vistagen Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Vistagen Therapeutics (Vistagen Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy.
Executives
Joshua S. Prince officer: Chief Operating Officer C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Cynthia Lynn Anderson officer: CHIEF FINANCIAL OFFICER C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Commodore Capital Lp 10 percent owner 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Jerry B Gin director 343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Reid G. Adler officer: CHIEF LEGAL OFFICER C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94090
Shawn Singh director, officer: CHIEF EXECUTIVE OFFICER C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Venrock Healthcare Capital Partners Ii, L.p. 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Ii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Eg, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Healthcare Capital Partners Eg, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Vhcp Co-investment Holdings Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Bong Y Koh 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Co-investment Holdings Ii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Nimish P Shah 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036

Vistagen Therapeutics (Vistagen Therapeutics) Headlines

From GuruFocus

Vistagen Announces Stockholder-Approved Reverse Stock Split

By Business Wire Business Wire 06-06-2023